You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Janus associated Kinase Inhibitor-Intolerant Myelofibrosis

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Sjogren's Syndrome Trial run by the National Institute of Dental and Craniofacial Research (NIDCR) (tofacitinib, Placebo)

Recruiting
  • Sjogren's Syndrome
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Nov 24, 2022

Myelofibrosis, Primary Myelofibrosis, Post-PV MF Trial in Canton (TL-895, Ruxolitinib)

Recruiting
  • Myelofibrosis
  • +3 more
  • Birmingham, Alabama
  • +13 more
Jan 10, 2023

Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV-MF), Post-Essential Thrombocythemia Myelofibrosis

Recruiting
  • Primary Myelofibrosis (PMF)
  • +2 more
  • Glendale, California
  • +28 more
May 5, 2022

Myelofibrosis Trial in Worldwide (TL-895)

Recruiting
  • Myelofibrosis
  • Aurora, Colorado
  • +65 more
Jun 2, 2022

Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis Trial in Worldwide (KRT-232, TL-895)

Recruiting
  • Myelofibrosis
  • +3 more
  • Birmingham, Alabama
  • +36 more
May 5, 2022

Myelofibrosis Trial in Worldwide (Imetelstat 4.7 mg/kg, Imetelstat 9.4 mg/kg)

Completed
Has Results
  • Myelofibrosis
  • Imetelstat 4.7 mg/kg
  • Imetelstat 9.4 mg/kg
  • Birmingham, Alabama
  • +71 more
Aug 17, 2021

Myelofibrosis Trial in Worldwide (Imetelstat, Best Available Therapy (BAT))

Recruiting
  • Myelofibrosis
  • La Jolla, California
  • +165 more
Aug 19, 2022

Janus Kinase Inhibitor Therapy in Ulcerative Colitis

Terminated
  • Ulcerative Colitis
  • Janus Kinase Inhibitor
  • Amsterdam, North Halland, Netherlands
    Amsterdam Medical Center, IBD Center
Dec 14, 2021

Acute Lung Injury (ALI) Associated With COVID-19, Lung Inflammation Associated With COVID-19 Trial in Worldwide (TD-0903,

Completed
Has Results
  • Acute Lung Injury (ALI) Associated With COVID-19
  • Lung Inflammation Associated With COVID-19
  • Duarte, California
  • +23 more
Mar 15, 2022

Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis Trial in Worldwide (Pelabresib, Ruxolitinib, Placebo)

Recruiting
  • Myelofibrosis
  • +3 more
  • Birmingham, Alabama
  • +148 more
Oct 10, 2022

Rheumatoid Arthritis Trial in London (Etanercept, tofacitinib)

Recruiting
  • Rheumatoid Arthritis
  • London, Ontario, Canada
    Rheumatology Clinic, St. Joseph's Health Care
May 10, 2022

Myelofibrosis Trial in Worldwide (Selinexor, Physician's Choice Treatment)

Recruiting
  • Myelofibrosis
  • Los Angeles, California
  • +41 more
Jan 30, 2023

Ruxolitinib in Patients With Myelofibrosis

Not yet recruiting
  • Myelofibrosis
  • (no location specified)
Feb 28, 2023

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive,

Completed
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +4 more
  • Eltrombopag Olamine
  • Houston, Texas
    M D Anderson Cancer Center
Jan 4, 2022

Myelofibrosis Trial in China (TQ05105 Tablets, TQB3617 Capsules)

Not yet recruiting
  • Myelofibrosis
  • TQ05105 Tablets
  • TQB3617 Capsules
  • Guangzhou, Guangdong, China
  • +19 more
Nov 7, 2023

Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis Trial in Worldwide (ACE-536, Placebo)

Recruiting
  • Myeloproliferative Disorders
  • +4 more
  • La Jolla, California
  • +184 more
Aug 22, 2022

Myelofibrosis Trial in Houston (Long-term Follow-up, Quality-of-Life Assessment, Ruxolitinib)

Active, not recruiting
  • Myelofibrosis
  • Long-term Follow-up
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 7, 2022

Moderate and High Risk Myelofibrosis Trial in China (TQ05105 tablets, Hydroxycarbamide tablets)

Recruiting
  • Moderate and High Risk Myelofibrosis
  • TQ05105 tablets
  • Hydroxycarbamide tablets
  • Beijing, Beijing, China
  • +3 more
Nov 23, 2021

Relapsed or Refractory Peripheral T Cell Lymphoma Trial in Worldwide (AZD4205)

Recruiting
  • Relapsed or Refractory Peripheral T Cell Lymphoma
  • New Haven, Connecticut
  • +50 more
Jan 27, 2022

Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Post-Essential Thrombocythemia MF (Post-ET-MF) Trial in

Recruiting
  • Primary Myelofibrosis (PMF)
  • +2 more
  • Birmingham, Alabama
  • +155 more
Aug 12, 2022

Primary Myelofibrosis, Secondary Myelofibrosis Trial in Seattle (procedure, drug, radiation)

Recruiting
  • Primary Myelofibrosis
  • Secondary Myelofibrosis
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +9 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jun 21, 2022

Myelofibrosis (PMF), Post Essential Thrombocythemia Myelofibrosis (ET-MF), Post Polycythemia Vera Related Myelofibrosis (PV-MF)

Not yet recruiting
  • Myelofibrosis (PMF)
  • +2 more
  • New York, New York
    Ruttenberg Treatment Center
Apr 18, 2023

Sarcoidosis Trial in New Haven (Abrocitinib 200 mg)

Not yet recruiting
  • Sarcoidosis
  • Abrocitinib 200 mg
  • New Haven, Connecticut
    Yale University
Jan 24, 2023

JAK Inhibition in Ulcerative Colitis

Not yet recruiting
  • Analyzing Immune Composition Changes Upon JAK Inhibitor Treatment of Ulcerative Colitis Patients
  • JAK inhibitor treatment
  • (no location specified)
Jul 11, 2022

Lupus or SLE, Nephritis Trial in Assiut (Baricitinib 4 MG, Baricitinib 2 MG, MMF)

Recruiting
  • Lupus or SLE
  • Nephritis
  • Baricitinib 4 MG
  • +2 more
  • Assiut, Yes, Egypt
    Manal Hassanien
Jan 13, 2023